KeifeRx is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative and immune diseases.
Industry
Biotechnology Research, Specialty (except Psychiatric and Substance Abuse) Hospitals, Health Care and Social Assistance
HQ Location
1356 Beverly Rd
300
McLean, Virginia 22101, US
Keywords
investment bankingview publicationmild cognitivetoxic proteinstoxic effectsoral capsuleabnormal levelsbulk disposalneurotoxic proteinclinical effects